1. Heme Oxygenase-1 Controls an HDAC4-miR-206 Pathway of Oxidative Stress in Rhabdomyosarcoma
   Maciej Ciesla et al, 2016, Cancer Research CrossRef
2. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells
   Eleanor O’Brien et al, 2023, Clinical Epigenetics CrossRef
3. Spatial control of adult stem cell fate using nanotopographic cues
   Eun Hyun Ahn et al, 2014, Biomaterials CrossRef
4. Reactive Oxygen Species (ROS)-Inducing Triterpenoid Inhibits Rhabdomyosarcoma Cell and Tumor Growth through Targeting Sp Transcription Factors
   Ravi Kasiappan et al, 2019, Molecular Cancer Research CrossRef
5. Simulated microgravity attenuates myogenesis and contractile function of 3D engineered skeletal muscle tissues
   Zhanping Ren et al, 2024, npj Microgravity CrossRef
6. A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
   Johanna Pruller et al, 2021, Cancer Gene Therapy CrossRef
7. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity
   Kay Nakazawa et al, 2023, Cancer Research Communications CrossRef
8. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy
   Venkatesh Rengaswamy et al, 2016, Journal of Controlled Release CrossRef
9. Sarcoma Pathology and Biology
   Marielle Yohe et al, 2021, Sarcomas of Bone and Soft Tissues in Children and Adolescents CrossRef
10. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1
    Alexandra Lacey et al, 2017, Cancer Research CrossRef
11. Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma
    Silvia Pomella et al, 2023, Cancers CrossRef
12. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas
    Edoardo Missiaglia et al, 2017, Cancer Letters CrossRef
13. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations
    Shinji Kohsaka et al, 2014, Nature Genetics CrossRef
14. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
    Alexandra Lacey et al, 2018, Molecular Cancer Therapeutics CrossRef
15. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models
    A. Kahsay et al, 2022, Scientific Reports CrossRef
16. Molecular Testing in Bone and Soft Tissue Tumors
    Brendan C. Dickson et al, 2014, Molecular Testing in Cancer CrossRef
17. Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma
    Erik Hedrick et al, 2019, Molecular Cancer Research CrossRef
18. The Importance of Being Dead: Cell Death Mechanisms Assessment in Anti-Sarcoma Therapy
    Santiago Rello-Varona et al, 2015, Frontiers in Oncology CrossRef